Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta JJ.

Leukemia. 2017 Jun;31(6):1446-1449. doi: 10.1038/leu.2017.58. Epub 2017 Feb 17. No abstract available.

2.

Immunotherapies targeting CD38 in Multiple Myeloma.

Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T.

Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016. Review.

PMID:
27999737
3.

Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, Omedè P.

Oncotarget. 2017 Jan 24;8(4):5924-5935. doi: 10.18632/oncotarget.12641.

4.

A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.

Ibata S, Sato T, Kuroda H, Nagamachi Y, Iyama S, Fujimi A, Kamihara Y, Konuma Y, Yoshida M, Tatekoshi A, Hashimoto A, Horiguchi H, Ono K, Murase K, Takada K, Miyanishi K, Kobune M, Hirayama Y, Kato J.

Cancer Chemother Pharmacol. 2016 Nov;78(5):1041-1049. Epub 2016 Oct 13.

5.

Recent advances in understanding multiple myeloma.

Dhakal B, Girnius S, Hari P.

F1000Res. 2016 Aug 23;5. pii: F1000 Faculty Rev-2053. doi: 10.12688/f1000research.8777.1. eCollection 2016. Review.

6.

Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.

Lee HS, Min CK.

Korean J Intern Med. 2016 Sep;31(5):809-19. doi: 10.3904/kjim.2016.110. Epub 2016 Sep 1. Review.

7.

Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma.

Lonial S.

Leuk Suppl. 2013 May;2(Suppl 1):S28-9. doi: 10.1038/leusup.2013.6. Epub 2013 May 8. Review. No abstract available.

8.

Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation.

Moreau P, Touzeau C.

Leuk Suppl. 2013 May;2(Suppl 1):S15-20. doi: 10.1038/leusup.2013.4. Epub 2013 May 8. Review.

9.

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.

Nishihori T, Song J, Shain KH.

Curr Hematol Malig Rep. 2016 Apr;11(2):118-26. doi: 10.1007/s11899-016-0308-3. Review.

10.

Multiple Myeloma: Treatment is Getting Individualized.

Agarwal MB.

Indian J Hematol Blood Transfus. 2016 Mar;32(1):3-9. doi: 10.1007/s12288-015-0575-5. Epub 2015 Jul 26. Review.

11.

Deep Response in Multiple Myeloma: A Critical Review.

Fulciniti M, Munshi NC, Martinez-Lopez J.

Biomed Res Int. 2015;2015:832049. doi: 10.1155/2015/832049. Epub 2015 Dec 10. Review.

12.

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.

Yousef S, Heise J, Lajmi N, Bartels K, Kröger N, Luetkens T, Atanackovic D.

J Transl Med. 2015 Jun 20;13:197. doi: 10.1186/s12967-015-0562-5.

13.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D.

Hum Vaccin Immunother. 2015;11(7):1606-11. doi: 10.1080/21645515.2015.1046658.

14.

Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities.

Mactier CE, Islam MS.

Oncol Rev. 2012 Oct 4;6(2):e14. doi: 10.4081/oncol.2012.e14. eCollection 2012 Oct 2. Review.

15.

New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Paiva B, van Dongen JJ, Orfao A.

Blood. 2015 May 14;125(20):3059-68. doi: 10.1182/blood-2014-11-568907. Epub 2015 Apr 2. Review.

16.

A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.

Navarro A, Díaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, Magnano L, Rosiñol L, Monzó M, Bladé J, Fernández de Larrea C.

Oncotarget. 2015 Jan 30;6(3):1874-83.

17.

Consolidation in multiple myeloma - current status and perspectives.

Olszewska-Szopa M, Rzepecki P.

Contemp Oncol (Pozn). 2014;18(5):313-7. doi: 10.5114/wo.2014.45983. Epub 2014 Nov 5. Review.

18.

Therapeutic advancements in multiple myeloma.

Gozzetti A, Candi V, Papini G, Bocchia M.

Front Oncol. 2014 Sep 4;4:241. doi: 10.3389/fonc.2014.00241. eCollection 2014. Review.

19.

The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

Orlowski RZ.

Oncology (Williston Park). 2011 Nov 15;25 Suppl 2:56-64. Review.

20.

The future of autologous stem cell transplantation in myeloma.

van Rhee F, Giralt S, Barlogie B.

Blood. 2014 Jul 17;124(3):328-33. doi: 10.1182/blood-2014-03-561985. Epub 2014 Jun 3. Review.

Supplemental Content

Support Center